Anika Therapeutics | ANIK - Interest Expense On Debt


Anika Therapeutics reported 179.39M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Abbott USD 68M 26M Mar/2026
Agenus USD 16.02M 2.85M Dec/2025
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.08M 517K Mar/2026
Integra LifeSciences USD 22.46M 1.21M Mar/2026
Intrexon USD 2K 5K Jun/2024
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
Merit Medical Systems USD 6.53M 162K Mar/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Smith & Nephew USD 69M 1000K Dec/2025
Stryker USD 46.29B 45.68B Mar/2026
Veracyte USD 2K 1000 Dec/2023
Xencor USD 4.7M 2.65M Mar/2026
Zimmer Biomet Holdings USD 68.8M 3.1M Mar/2026